Gilead Sciences Inc. may not get the US Supreme Court to tackle a question that has the potential to derail certain False Claims Act cases before they go to trial. But if the government gets its way, a complaint alleging Gilead made misrepresentations to FDA involving an active ingredient in its HIV drugs will get dismissed.
The Solicitor General has advised the court not to grant review of Gilead Sciences v. United States ex rel. Campie,...





